NL-OMON42215已完成不适用
Human Cerenkov Luminescence Imaging of Superficial In-Vivo Tumours after Administration of 18F-FDG - Feasibility of In-vivo Human Cerenkov Imaging
ederlands Kanker Instituut0 个研究点目标入组 12 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients, older than 18 years, who will receive and 18F-FDG PET-CT scan and have a superficial tumour, <3 cm from surface, that shows sufficient uptake of 18F-FDG.
排除标准
- •Patient younger than 18 years.
- •Patients with a melanoma with a high melanin level.
研究者
相似试验
已完成
不适用
Non-Invasive Cerenkov Luminescence Imaging of Lymphoma, Leukemia and Metastatic Lymph NodesHead and Neck CancersNCT01664936Memorial Sloan Kettering Cancer Center27
招募中
不适用
aparoscopic laser speckle contrast imaging for the demarcation of lung segmentsLungcancer1002910710038737NL-OMON51469IMIS Development BV10
招募中
不适用
A feasibility study on Cerenkov Luminescence Imaging using Gallium-68 PSMA during prostate cancer surgeryprostate carcinoma1003695810025506Prostate cancerNL-OMON48989Antoni van Leeuwenhoek Ziekenhuis30
进行中（未招募）
1 期
Amyloid imaging in Alzheimer’s disease, frontotemporal dementia and healthy volunteersse of 18F-AV-45 positron emission tomography as early diagnostic technique in frontal lobe dementia and Alzheimer's disease.MedDRA version: 14.0 Level: PT Classification code 10061816 Term: Diagnostic procedure System Organ Class: 10022891 - InvestigationsEUCTR2008-003597-18-GBAvid Radiopharmaceuticals, Inc34
已完成
2 期
Amyloid imaging in Alzheimer's disease, frontotemporal dementia and healthy volunteersFrontotemporal dementia and Alzheimer's diseaseNervous System DiseasesAlzheimer's diseaseISRCTN58435532Avid Radiopharmaceuticals Inc.40